The safety and effectiveness of combining medications will depend on a patients individual health conditions and the specific medications involved
The relationship between GLP-1 receptor agonists and inflammation remains an active area of clinical investigation, with ongoing studies exploring mechanisms and clinical applications beyond traditional metabolic indications
It is alleged that the manufacturers, Novo Nordisk and Eli Lilly knew or should have known about the risks associated with these drugs and failed to warn consumers
Possible effect modification by age, sex, diabetes status, glycemic control, obesity, CVD, and other comorbidities, as well as compounds, administration methods, and dosages of GLP-1 RAs should be evaluated
Journal of Crohns and Colitis